Skip to main content

Table 1 Clinicopathological features of the screening cohort

From: miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma

Variable

No. of patients n = 167

Bone marrow CD138+ plasma cells n = 167

Peripheral blood plasma n = 69

Disease

 sMM

28 (16.8%)

 MM

139 (83.2%)

69 (100.0%)

Multiple myeloma patients

 R-ISS stage

 R-ISS I

34 (24.5%)

20 (29.0%)

 R-ISS II

68 (48.9%)

28 (40.6%)

 R-ISS III

28 (20.1%)

14 (20.3%)

 No data

9

7

ISS Stage

 ISS I

40 (28.8%)

25 (36.2%)

 ISS II

43 (30.9%)

19 (27.5%)

 ISS III

55 (39.6%)

24 (34.8%)

 No data

1

1

Gender

 Male

77 (55.4%)

38 (55.1%)

 Female

62 (44.6%)

31 (44.9%)

Therapy

 Bortezomib-based regimens

122 (87.8%)

65 (94.2%)

 Lenalidomide-dexamethasone

12 (8.6%)

4 (5.8%)

 Other

2 (1.4%)

0

 Not complete treatment

3 (2.2%)

0

Bone disease

 Yes

92 (66.2%)

42 (60.9%)

 No

38 (27.3%)

27 (39.1%)

 No data

9

0

HDM/ASCT

 Yes

38 (27.3%)

28 (40.6%)

 No

100 (71.9%)

41 (59.4%)

 No data

1

0

B2M

  < 3.5 mg/l

43 (30.9%)

26 (37.7%)

  ≥ 3.5 mg/l and < 5.5 mg/l

41 (29.5%)

19 (27.5%)

  > 5.5 mg/l

54 (38.8%)

23 (33.3%)

 No data

1

1

LDH

  ≤ 220 U/l

107 (77.0%)

54 (78.3%)

  > 220 U/l

32 (23.0%)

15 (21.7%)

Marrow plasma cells

  < 60%

58 (41.7%)

33 (47.8%)

  ≥ 60%

81 (58.3%)

36 (52.2%)

Response to 1st line

 sCR / CR / VGPR

90 (64.7%)

47 (68.1%)

 PR / SD / PD

45 (32.4%)

22 (30.4%)

 No data

4

0

Disease monitoring

 Follow-up patients

135

69

 Relapse

33 (24.4%)

17 (24.6%)

 Death

30 (22.2%)

13 (18.8%)

 Progression

49 (36.3%)

25 (36.2%)

 Excluded from follow-up

4

0

  1. HDM/ASCT: high-dose melphalan therapy with autologous stem cell transplantation, sCR: stringent complete response, CR: complete response, VGPR: very good partial response, PR: partial response, SD: stable disease, PD: progressed disease